MiMedx Group (NASDAQ:MDXG) Sets New 52-Week Low – Should You Sell?

MiMedx Group, Inc (NASDAQ:MDXG) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $4.80 and last traded at $4.94, with a volume of 2595097 shares traded. The stock had previously closed at $5.28.

Trending Headlines about MiMedx Group

Here are the key news stories impacting MiMedx Group this week:

• Positive Sentiment: Company reported strong Q4/2025 revenue growth and strategic progress on its earnings call — positive operational signs that support longer‑term recovery. MiMedx Q4 2025 Earnings Call Highlights
• Positive Sentiment: Analysts’ consensus price target sits at $9.50, implying significant upside from current levels if execution continues and guidance reaccelerates. Consensus Price Target
• Positive Sentiment: Wall Street Zen moved the stock to a Buy rating (market coverage note), which can support demand if other shops follow or reaffirm. Wall Street Zen Rating Change
• Negative Sentiment: Northland Securities lowered multiple near‑term and full‑year EPS forecasts (Q1 2026 to ($0.03), Q2 to $0.01 from $0.03, Q3 to $0.03 from $0.04, Q4 to $0.04 from $0.05) and cut FY2026 guidance sharply (from $0.12 prior to $0.04 now); FY2027 was trimmed to $0.15 from $0.20 — these cuts signal slower margin or revenue timing and are pressuring the stock.

Analysts Set New Price Targets

MDXG has been the topic of several analyst reports. UBS Group set a $10.00 price objective on MiMedx Group in a report on Monday, February 23rd. Citigroup initiated coverage on MiMedx Group in a research report on Monday, February 23rd. They set a “market outperform” rating on the stock. Cantor Fitzgerald decreased their price target on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 17th. Lake Street Capital dropped their price objective on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 20th. Finally, Mizuho decreased their target price on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 17th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.60.

MiMedx Group Stock Down 1.0%

The stock has a fifty day moving average price of $5.70 and a 200-day moving average price of $6.57. The firm has a market cap of $726.51 million, a PE ratio of 15.28 and a beta of 1.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a net margin of 11.60% and a return on equity of 30.61%. The firm had revenue of $118.10 million for the quarter, compared to analysts’ expectations of $106.78 million. Research analysts expect that MiMedx Group, Inc will post 0.3 EPS for the current year.

Institutional Trading of MiMedx Group

A number of institutional investors have recently added to or reduced their stakes in MDXG. CWM LLC raised its position in MiMedx Group by 63.8% in the second quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after purchasing an additional 1,892 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of MiMedx Group in the fourth quarter valued at about $48,000. PNC Financial Services Group Inc. grew its stake in shares of MiMedx Group by 1,808.4% in the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock valued at $46,000 after buying an additional 7,107 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of MiMedx Group during the 3rd quarter valued at about $54,000. Finally, Jain Global LLC acquired a new position in MiMedx Group during the 4th quarter worth approximately $73,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.